A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome
about
Chronic fatigue syndrome: aetiology, diagnosis and treatmentInterventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic reviewA status report on chronic fatigue syndrome.A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndromeChronic fatigue syndrome: reviewing the research findings.Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells.Chronic fatigue syndrome: new insights and old ignorance.Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.Interventions for the treatment and management of chronic fatigue syndrome/myalgic encephalomyelitisChronic fatigue syndrome and fibromyalgia: clinical assessment and treatment.alpha-Interferon treatment of patients with chronic fatigue syndrome.Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Rapid, non-invasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals.Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacityMood and Global Symptom Changes among Psychotherapy Clients with Depressive Personality.Targeting toll-like receptors for drug development: a summary of commercial approaches.TLR3 agonists and proinflammatory antitumor activities.Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Prophylactic and therapeutic implications of toll-like receptor ligands.Vaccine adjuvant uses of poly-IC and derivatives.Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.Chronic fatigue syndrome. 2: Treatment and future research.Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2).Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.Dose-related effects of Ampligen (poly(I).poly(C12U)), a mismatched double-stranded RNA, in a bleomycin-mouse model of pulmonary fibrosis.Enhanced expression of brain interferon-alpha and serotonin transporter in immunologically induced fatigue in rats.
P2860
Q21260252-61E3F750-DEE8-498C-B08F-4F724F5CE92AQ22241583-04EEF06D-7326-457C-9484-5B1B4F4CF03AQ24529955-08D729FF-F30A-42F6-B756-D83CD866F7F1Q28481488-E6881FA8-3785-494A-84A0-FA3F45AD719EQ33179434-6E76F752-8B8C-41DB-8AD3-798C195DBDDCQ33244320-55C368F1-F68D-43F2-A500-FB1DCAA20813Q33503856-69AE3CFF-BF0E-45F8-BCD1-45B647A4A9CEQ33785889-B65A4964-AE01-45D5-8622-B81A463CA16AQ34022013-F2D51950-C511-4A8C-8C44-3F10C765607DQ34165444-3659BDC8-5A27-47A9-AC17-76296BB8785BQ34187505-F1E0978F-5238-4B59-98C9-7B618E0E929FQ34386229-4DA3EDB6-15CC-4CD4-9D78-7050E61F4A36Q34520840-12DEE70A-622B-4FD5-9DBD-CBBEAD0F880DQ34680436-5D2D75B6-D000-4F1B-89F8-91264FF997C8Q35018021-BAC861C7-FB29-4395-8378-02AFE57FFF06Q35608085-36362D89-F64B-4106-97AC-1A4C63DC5F00Q35887255-B38D603C-95EA-44AB-9F5D-C69CFCA049CDQ36490394-4CD8E2E5-C77D-497E-BEC1-F912A6EC8901Q36898653-BC8EBE4D-4473-4540-B9AA-05669810261DQ37136200-21B7E0BD-314C-4C12-8F61-042A27B00E3CQ37678427-F5FAECFA-8686-45F3-B81D-D43525FCFC9DQ37873932-F642CD9B-88C8-40D5-9642-90E5BD4FAF8BQ37989884-B676819C-5539-4368-ADA7-727A445FFFDFQ38259510-5D03B661-D72E-49CA-B63E-B2FFFD89FF29Q38650323-C3ADA2D8-1081-45F7-91AE-214535534830Q40425431-A576A378-D1A4-470A-8D5C-6AD497A78C26Q44684461-5FF7BCAC-4D70-4490-BADF-5B117D6A3C83Q45404856-B8BBEBAB-D8A8-4438-B2E4-505809F2CAB9Q45942099-E022A209-00D9-47BE-BF6E-58BB47AB279CQ46832704-2DA31050-8303-4655-B6AE-28433D75DC34
P2860
A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@ast
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@en
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@nl
type
label
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@ast
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@en
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@nl
prefLabel
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@ast
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@en
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@nl
P2093
P3181
P1476
A controlled clinical trial wi ...... ), in chronic fatigue syndrome
@en
P2093
C Thompson
D E Shapiro
D Peterson
D R Strayer
M Loveless
W A Carter
W Elsasser
P304
P3181
P356
10.1093/CLINIDS/18.SUPPLEMENT_1.S88
P407
P478
18 Suppl 1
P577
1994-01-01T00:00:00Z